RVSV Pseudotyped EBOV GP
Order now: dominika@ksiazkiwnauce.pl
EBOV Soluble GP (sGP) ELISA kit |
|||
0100-001 | IBT Bioservices | 1ea | 662.4 EUR |
Description:
|
|||
Mouse anti-EBOV GP mAb (4F3) |
|||
0201-020 | IBT Bioservices | 100ug | 577.2 EUR |
Description:
|
|||
Chimeric anti-EBOV GP mAb (c6D8) |
|||
0201-021 | IBT Bioservices | 100ug | 577.2 EUR |
Description:
|
|||
Chimeric anti-EBOV GP mAb (h13F6) |
|||
0201-022 | IBT Bioservices | 100ug | 577.2 EUR |
Description:
|
|||
Human anti-EBOV GP mAb (KZ52) |
|||
0260-001 | IBT Bioservices | 100ug | 577.2 EUR |
Description:
|
|||
Rabbit anti-EBOV GP pAb Biotinylated |
|||
0301-015-bio | IBT Bioservices | 100ug | 729.6 EUR |
Description:
|
|||
Recombinant EBOV Soluble gp Protein [His] |
|||
VAng-Lsx0143-inquire | Creative Biolabs | inquire | Ask for price |
Description: EBOV sGP, recombinant protein from mammalian cells. |
|||
h HA-kRas G12V (GP) |
|||
LVP799-GP | GenTarget | 1x107 IFU/ml x 200ul | 541.2 EUR |
Description: Pre-made over-expression lentivirus for expressing human target: G12V mutant of kRas. Except the point mutation, the sub-cloned codon sequence is identical (100% match) to CDS region in NCBI ID: NM_004985. It also contains a GFP-Puromycin dual selection marker. |
|||
h VEGFA inducible lentiviral particles (GP) |
|||
LVP388-GP | GenTarget | 1 x107 IFU/ml x 200ul | 541.2 EUR |
Description: Pre-made inducible lentiviral particles for expressing human target: h VEGFA (alternative name: VPF; VEGF; MVCD1; MGC70609), with ORF sequence 100% matching to CDS region in NCBI ID: NM_001171626.1. Particles has GFP-Puromycin dual marker. |
|||
h CXCL12 inducible lentiviral particles (GP) |
|||
LVP698-GP | GenTarget | 1x107 IFU/ml x 200ul | 541.2 EUR |
Description: Pre-made over-expression lentivirus for expressing human target: CXCL12 (chemokine (C-X-C motif) ligand 12), [alternative names: IRH; PBSF; SCYB12; SDF1; TLSF; TPAR1]. The sub-cloned codon sequence is identical (100% match) to CDS region in NCBI ID: NM_199168.3. It also contains a GFP-Puromycin dual selection marker. |
|||
Chimeric anti-EBOV GP mAb (c13C6 FR1) |
|||
0201-023 | IBT Bioservices | 100ug | 577.2 EUR |
Description:
|
|||
Rabbit anti-EBOV Soluble GP (sGP) pAb |
|||
0365-001 | IBT Bioservices | 100ug | 577.2 EUR |
Description:
|
|||
Recombinant EBOV gp Protein (aa 1-647) |
|||
VAng-Lsx0140-100g | Creative Biolabs | 100 µg | 1210.8 EUR |
Description: Ebola glycoprotein (aa 1-647), recombinant protein from 293 cell culture. |
|||
Recombinant EBOV gp Protein (Minus The Transmembrane Region) [His] |
|||
VAng-Lsx0141-inquire | Creative Biolabs | inquire | Ask for price |
Description: EBOV GPDTM, recombinant protein from Sf9 cells. |
|||
Recombinant EBOV gp Protein (Minus The Transmembrane Region) [HA] |
|||
VAng-Lsx0142-inquire | Creative Biolabs | inquire | Ask for price |
Description: EBOV GPDTM, recombinant protein from mammalian cells. |
|||
Recombinant EBOV GP-RBD Protein (aa 1-308) [Fc] |
|||
VAng-Wyb6914-100g | Creative Biolabs | 100 µg | 2281.2 EUR |
Description: Ebola virus (subtype Zaire, strain Mayinga 1976) Glycoprotein, recombinant protein. |
|||
Recombinant EBOV GP-RBD Protein (aa 1-308) [Fc] |
|||
VAng-Wyb6914-20g | Creative Biolabs | 20 µg | 940.8 EUR |
Description: Ebola virus (subtype Zaire, strain Mayinga 1976) Glycoprotein, recombinant protein. |
|||
Recombinant EBOV GP-RBD Protein (aa 1-320) [Fc] |
|||
VAng-Wyb6917-100g | Creative Biolabs | 100 µg | 2281.2 EUR |
Description: Ebola virus (subtype Sudan, strain Gulu) Glycoprotein, recombinant protein. |
|||
Recombinant EBOV GP-RBD Protein (aa 1-320) [Fc] |
|||
VAng-Wyb6917-20g | Creative Biolabs | 20 µg | 940.8 EUR |
Description: Ebola virus (subtype Sudan, strain Gulu) Glycoprotein, recombinant protein. |
|||
NATtrol BC/GP Panel (10 X 0.75 mL) |
|||
NATBC/GP-NNS | Zeptometrix | 10 X 0.75 mL | 751.39 EUR |
Description: Please contact Gentaur in order to receive the datasheet of the product. |
|||
Recombinant Reston EBOV gp Protein (Minus The Transmembrane Region) [His] |
|||
VAng-Lsx0145-inquire | Creative Biolabs | inquire | Ask for price |
Description: rREBOV GPDTM, recombinant protein from Sf9 cells. |
|||
Recombinant EBOV GP Protein (aa 1-501) [His] (HEK293 Cells) |
|||
VAng-Wyb6904-100g | Creative Biolabs | 100 µg | 2281.2 EUR |
Description: Ebola virus (subtype Sudan, strain Gulu) Glycoprotein, recombinant protein. |
|||
Recombinant EBOV GP Protein (aa 1-501) [His] (HEK293 Cells) |
|||
VAng-Wyb6904-20g | Creative Biolabs | 20 µg | 940.8 EUR |
Description: Ebola virus (subtype Sudan, strain Gulu) Glycoprotein, recombinant protein. |
|||
Recombinant EBOV GP Protein (aa 1-637) [His] (HEK293 Cells) |
|||
VAng-Wyb6906-100g | Creative Biolabs | 100 µg | 2281.2 EUR |
Description: Ebola virus (subtype Sudan, strain Gulu) Glycoprotein, recombinant protein. |
|||
Recombinant EBOV GP Protein (aa 1-637) [His] (HEK293 Cells) |
|||
VAng-Wyb6906-20g | Creative Biolabs | 20 µg | 940.8 EUR |
Description: Ebola virus (subtype Sudan, strain Gulu) Glycoprotein, recombinant protein. |
|||
Recombinant EBOV GP Protein (aa 1-650) [His] (HEK293 Cells) |
|||
VAng-Wyb6909-100g | Creative Biolabs | 100 µg | 2281.2 EUR |
Description: Ebola virus (subtype Zaire, strain H.sapiens-wt/GIN/2014/Kissidougou-C15) Glycoprotein, recombinant protein. |
|||
Recombinant EBOV GP Protein (aa 1-650) [His] (HEK293 Cells) |
|||
VAng-Wyb6909-20g | Creative Biolabs | 20 µg | 940.8 EUR |
Description: Ebola virus (subtype Zaire, strain H.sapiens-wt/GIN/2014/Kissidougou-C15) Glycoprotein, recombinant protein. |
|||
Recombinant EBOV GP Protein (aa 1-501) [His] (Baculovirus-Insect Cells) |
|||
VAng-Wyb6903-100g | Creative Biolabs | 100 µg | 2281.2 EUR |
Description: Ebola virus (subtype Sudan, strain Gulu) Glycoprotein, recombinant protein. |
|||
Recombinant EBOV GP Protein (aa 1-501) [His] (Baculovirus-Insect Cells) |
|||
VAng-Wyb6903-20g | Creative Biolabs | 20 µg | 940.8 EUR |
Description: Ebola virus (subtype Sudan, strain Gulu) Glycoprotein, recombinant protein. |
|||
Recombinant EBOV GP Protein (aa 1-637) [His] (Baculovirus-Insect Cells) |
|||
VAng-Wyb6905-100g | Creative Biolabs | 100 µg | 2281.2 EUR |
Description: Ebola virus (subtype Sudan, strain Uganda-00) Glycoprotein, recombinant protein. |
|||
Recombinant EBOV GP Protein (aa 1-637) [His] (Baculovirus-Insect Cells) |
|||
VAng-Wyb6905-20g | Creative Biolabs | 20 µg | 940.8 EUR |
Description: Ebola virus (subtype Sudan, strain Uganda-00) Glycoprotein, recombinant protein. |
|||
Recombinant EBOV GP Protein (aa 1-650) [His] (Baculovirus-Insect Cells) |
|||
VAng-Wyb6908-100g | Creative Biolabs | 100 µg | 2281.2 EUR |
Description: Ebola virus (subtype Zaire, strain H.sapiens-wt/GIN/2014/Kissidougou-C15) Glycoprotein, recombinant protein. |
|||
Recombinant EBOV GP Protein (aa 1-650) [His] (Baculovirus-Insect Cells) |
|||
VAng-Wyb6908-20g | Creative Biolabs | 20 µg | 940.8 EUR |
Description: Ebola virus (subtype Zaire, strain H.sapiens-wt/GIN/2014/Kissidougou-C15) Glycoprotein, recombinant protein. |
|||
Recombinant EBOV GP Protein (aa 1-650, 309-484 deleted) [His] |
|||
VAng-Wyb6910-100g | Creative Biolabs | 100 µg | 2281.2 EUR |
Description: Ebola virus (subtype Zaire, strain H.sapiens-wt/GIN/2014/Kissidougou-C15) Glycoprotein (Virion spike glycoprotein), recombinant protein. |
|||
Recombinant EBOV GP Protein (aa 1-650, 309-484 deleted) [His] |
|||
VAng-Wyb6910-20g | Creative Biolabs | 20 µg | 940.8 EUR |
Description: Ebola virus (subtype Zaire, strain H.sapiens-wt/GIN/2014/Kissidougou-C15) Glycoprotein (Virion spike glycoprotein), recombinant protein. |
|||
Zaire Ebola Virus Glycoprotein (EBOV GP antigen) ELISA Kit, 48 tests, Quantitative |
|||
AE-320800-48 | Alpha Diagnostics | 1 kit | 1074 EUR |
Zaire Ebola Virus Glycoprotein (EBOV GP antigen) ELISA Kit, 96 tests, Quantitative |
|||
AE-320800-96 | Alpha Diagnostics | 1 kit | 1804.8 EUR |
Mouse Monoclonal Anti-Anti-Zaire Ebola virus glycoprotein (EBOV GP) IgG, purified |
|||
EVGP20-M | Alpha Diagnostics | 100 ul | 578.4 EUR |
Recombinant EBOV GP Protein (aa 1-650) [His] (subtype Zaire, strain Mayinga 1976) |
|||
VAng-Wyb6907-100g | Creative Biolabs | 100 µg | 2281.2 EUR |
Description: Ebola virus (subtype Zaire, strain Mayinga 1976) Glycoprotein, recombinant protein. |
|||
Recombinant EBOV GP Protein (aa 1-650) [His] (subtype Zaire, strain Mayinga 1976) |
|||
VAng-Wyb6907-20g | Creative Biolabs | 20 µg | 940.8 EUR |
Description: Ebola virus (subtype Zaire, strain Mayinga 1976) Glycoprotein, recombinant protein. |
|||
Recombinant EBOV VP24 |
|||
0501-030 | IBT Bioservices | 100ug | 589.2 EUR |
Description:
|
|||
EBOV Delta Peptide |
|||
0509-001 | IBT Bioservices | 100ug | 589.2 EUR |
Description:
|
|||
Recombinant EBOV VP40 |
|||
0564-001 | IBT Bioservices | 100ug | 589.2 EUR |
Description:
|
|||
Recombinant EBOV Protein |
|||
VAng-Lsx0136-1mg | Creative Biolabs | 1 mg | 1365.6 EUR |
Description: EBOV, recombinant protein from E. coli. |
|||
Recombinant EBOV VLPs |
|||
VAng-Lsx0139-inquire | Creative Biolabs | inquire | Ask for price |
Description: EBOV Virus-Like Particles, recombinant protein from Sf9 cells. |
|||
GP- |
|||
EF017774 | Lifescience Market | 96 Tests | 826.8 EUR |
GP |
|||
EF013650 | Lifescience Market | 96 Tests | 826.8 EUR |
GP |
|||
EF006873 | Lifescience Market | 96 Tests | 826.8 EUR |
Recombinant EBOV GP-RBD Protein (aa 1-308) [His] (subtype Zaire, strain Mayinga 1976) |
|||
VAng-Wyb6915-100g | Creative Biolabs | 100 µg | 2281.2 EUR |
Description: Ebola virus (subtype Zaire, strain Mayinga 1976) Glycoprotein, recombinant protein. |
|||
Recombinant EBOV GP-RBD Protein (aa 1-308) [His] (subtype Zaire, strain Mayinga 1976) |
|||
VAng-Wyb6915-20g | Creative Biolabs | 20 µg | 940.8 EUR |
Description: Ebola virus (subtype Zaire, strain Mayinga 1976) Glycoprotein, recombinant protein. |
|||
Recombinant EBOV GPDTM (mammalian) |
|||
0501-001 | IBT Bioservices | 100ug | 662.4 EUR |
Description:
|
|||
Recombinant EBOV GPDTM (Sf9) |
|||
0501-015 | IBT Bioservices | 100ug | 589.2 EUR |
Description:
|
|||
Recombinant EBOV GPDTM (Sf9) |
|||
0501-016 | IBT Bioservices | 500ug | 2179.2 EUR |
Description:
|
|||
Recombinant EBOV GPDTM (S2) |
|||
0501-025 | IBT Bioservices | 100ug | 662.4 EUR |
Description:
|
|||
Recombinant EBOV GPDTM (S2) |
|||
0501-026 | IBT Bioservices | 500ug | 2470.8 EUR |
Description:
|
|||
Recombinant EBOV GPΔmuc (Sf9) |
|||
0511-015 | IBT Bioservices | 100ug | 589.2 EUR |
Description:
|
|||
Recombinant EBOV Zaire NP |
|||
VAng-Lsx0137-inquire | Creative Biolabs | inquire | Ask for price |
Description: Recombinant Ebola Zaire Nucleoprotein (NP), contains the C-terminal portion of the Ebola Zaire nucleoprotein. Molecular weight is 15 kDa. |
|||
GP Antibody |
|||
1-CSB-PA350772LA01ZAT | Cusabio |
|
|
Description: A polyclonal antibody against GP. Recognizes GP from Zaire ebolavirus. This antibody is Unconjugated. Tested in the following application: ELISA |
|||
GP Antibody |
|||
1-CSB-PA308957LA01ZAA | Cusabio |
|
|
Description: A polyclonal antibody against GP. Recognizes GP from Zaire ebolavirus. This antibody is Unconjugated. Tested in the following application: ELISA, WB; Recommended dilution: WB:1:500-1:5000 |
|||
GP Antibody |
|||
1-CSB-PA310843LA01ZAA | Cusabio |
|
|
Description: A polyclonal antibody against GP. Recognizes GP from Zaire ebolavirus. This antibody is Unconjugated. Tested in the following application: ELISA |
|||
GP Antibody |
|||
1-CSB-PA314099LA01ZAT | Cusabio |
|
|
Description: A polyclonal antibody against GP. Recognizes GP from Zaire ebolavirus. This antibody is Unconjugated. Tested in the following application: ELISA |
|||
P-gp/ Rat P- gp ELISA Kit |
|||
ELA-E1690r | Lifescience Market | 96 Tests | 1063.2 EUR |
GP-IIbIIIa/ Rat GP- IIbIIIa ELISA Kit |
|||
ELA-E0614r | Lifescience Market | 96 Tests | 1063.2 EUR |
GP-IV/ Rat GP- IV ELISA Kit |
|||
ELA-E0674r | Lifescience Market | 96 Tests | 1063.2 EUR |
GP-BB/ Rat GP- BB ELISA Kit |
|||
ELA-E0845r | Lifescience Market | 96 Tests | 1063.2 EUR |
GP-MM/ Rat GP- MM ELISA Kit |
|||
ELA-E0848r | Lifescience Market | 96 Tests | 1063.2 EUR |
GP-II/ Rat GP- II ELISA Kit |
|||
ELA-E0849r | Lifescience Market | 96 Tests | 1063.2 EUR |
Rabbit anti-EBOV VLP antiserum |
|||
01-0004 | IBT Bioservices | 250uL | 460.8 EUR |
Description:
|
|||
Rabbit anti-EBOV VP40 pAb |
|||
0301-010 | IBT Bioservices | 100ug | 577.2 EUR |
Description:
|
|||
Rabbit anti-EBOV NP pAb |
|||
0301-012 | IBT Bioservices | 100ug | 577.2 EUR |
Description:
|
|||
Rabbit anti-EBOV VP35 pAb |
|||
0301-040 | IBT Bioservices | 100ug | 577.2 EUR |
Description:
|
|||
Rabbit anti-EBOV VP24 pAb |
|||
0301-046 | IBT Bioservices | 100ug | 577.2 EUR |
Description:
|
|||
Rabbit anti-EBOV VP24 pAb |
|||
0301-047 | IBT Bioservices | 100ug | 577.2 EUR |
Description:
|
|||
Rabbit anti-EBOV VP30 pAb |
|||
0301-048 | IBT Bioservices | 100ug | 577.2 EUR |
Description:
|
|||
Rabbit anti-EBOV VLP pAb |
|||
0315-001 | IBT Bioservices | 500ug | 577.2 EUR |
Description:
|
|||
Rabbit anti-EBOV Delta Peptide |
|||
0366-001 | IBT Bioservices | 100ug | 577.2 EUR |
Description:
|
|||
Recombinant EBOV Zaire NP [His] |
|||
VAng-Lsx0138-inquire | Creative Biolabs | inquire | Ask for price |
Description: Ebola Zaire nucleoprotein, recombinant protein from E. coli. |
|||
Recombinant EBOV VP40 Matrix Protein |
|||
VAng-Lsx0144-100g | Creative Biolabs | 100 µg | 712.8 EUR |
Description: EBOV VP40, recombinant protein from E. coli. |
|||
Recombinant HIV gp 120 and gp 41 Protein |
|||
VAng-0533Lsx-inquire | Creative Biolabs | inquire | Ask for price |
Description: HIV Chimeric Recombinant protein containing C-terminal of gp120 and most of gp41, expressed in E. coli. MW 27.3 kDa, 1.00 mg/mL. |
|||
Recombinant EBOV GP-RBD Protein (aa 1-308) [His] (subtype Zaire, strain H.sapiens-wt/GIN/2014/Kissidougou-C15) |
|||
VAng-Wyb6916-100g | Creative Biolabs | 100 µg | 2281.2 EUR |
Description: Ebola virus (subtype Zaire, strain H.sapiens-wt/GIN/2014/Kissidougou-C15) Glycoprotein, recombinant protein. |
|||
Recombinant EBOV GP-RBD Protein (aa 1-308) [His] (subtype Zaire, strain H.sapiens-wt/GIN/2014/Kissidougou-C15) |
|||
VAng-Wyb6916-20g | Creative Biolabs | 20 µg | 940.8 EUR |
Description: Ebola virus (subtype Zaire, strain H.sapiens-wt/GIN/2014/Kissidougou-C15) Glycoprotein, recombinant protein. |
|||
proDynorphin (GP Reactive) |
|||
P10115 | Neuromics | 20 ug Blocking Peptide | 175.2 EUR |
GP(33-41) |
|||
HY-P0323 | MedChemExpress | 10mg | 456 EUR |
proDynorphin (GP Reactive) |
|||
GP10109 | Neuromics | 50 ul | 321.6 EUR |
GP Polyclonal Antibody |
|||
A64246-020 | EpiGentek | 20 ul | 117.7 EUR |
GP Polyclonal Antibody |
|||
A64246-050 | EpiGentek | 50 ul | 302.5 EUR |
GP Polyclonal Antibody |
|||
A64246-100 | EpiGentek | 100 ul | 423.5 EUR |
GP Polyclonal Antibody |
|||
A64254-020 | EpiGentek | 20 ul | 117.7 EUR |
GP Polyclonal Antibody |
|||
A64254-050 | EpiGentek | 50 ul | 302.5 EUR |
GP Polyclonal Antibody |
|||
A64254-100 | EpiGentek | 100 ul | 423.5 EUR |
GP Polyclonal Antibody |
|||
A64414-020 | EpiGentek | 20 ul | 117.7 EUR |
GP Polyclonal Antibody |
|||
A64414-050 | EpiGentek | 50 ul | 302.5 EUR |
GP Polyclonal Antibody |
|||
A64414-100 | EpiGentek | 100 ul | 423.5 EUR |
GP Polyclonal Antibody |
|||
A64246 | EpiGentek |
|
|
GP Polyclonal Antibody |
|||
A64254 | EpiGentek |
|
|
GP Polyclonal Antibody |
|||
A64414 | EpiGentek |
|
|
Mouse anti-EBOV VP40 mAb (3G5) |
|||
0201-016 | IBT Bioservices | 100ug | 577.2 EUR |
Description:
|
|||
Mouse anti-EBOV VP40 mAb (5B12) |
|||
0201-017 | IBT Bioservices | 100ug | 577.2 EUR |
Description:
|
|||
Mouse anti-EBOV VP40 mAb (AE11) |
|||
0201-018 | IBT Bioservices | 100ug | 577.2 EUR |
Description:
|
|||
Rabbit anti-EBOV L-Polymerase pAb |
|||
0301-045 | IBT Bioservices | 100ug | 577.2 EUR |
Description:
|
|||
Ebola virus-like particles (EBOV VLP) |
|||
0550-001 | IBT Bioservices | 1mg | 662.4 EUR |
Description:
|
|||
GP Antibody, HRP conjugated |
|||
1-CSB-PA350772LB01ZAT | Cusabio |
|
|
Description: A polyclonal antibody against GP. Recognizes GP from Zaire ebolavirus. This antibody is HRP conjugated. Tested in the following application: ELISA |
|||
GP Antibody, FITC conjugated |
|||
1-CSB-PA350772LC01ZAT | Cusabio |
|
|
Description: A polyclonal antibody against GP. Recognizes GP from Zaire ebolavirus. This antibody is FITC conjugated. Tested in the following application: ELISA |
|||
GP Antibody, Biotin conjugated |
|||
1-CSB-PA350772LD01ZAT | Cusabio |
|
|
Description: A polyclonal antibody against GP. Recognizes GP from Zaire ebolavirus. This antibody is Biotin conjugated. Tested in the following application: ELISA |
|||
GP Antibody, HRP conjugated |
|||
1-CSB-PA308957LB01ZAA | Cusabio |
|
|
Description: A polyclonal antibody against GP. Recognizes GP from Zaire ebolavirus. This antibody is HRP conjugated. Tested in the following application: ELISA |
|||
GP Antibody, FITC conjugated |
|||
1-CSB-PA308957LC01ZAA | Cusabio |
|
|
Description: A polyclonal antibody against GP. Recognizes GP from Zaire ebolavirus. This antibody is FITC conjugated. Tested in the following application: ELISA |
|||
GP Antibody, Biotin conjugated |
|||
1-CSB-PA308957LD01ZAA | Cusabio |
|
|
Description: A polyclonal antibody against GP. Recognizes GP from Zaire ebolavirus. This antibody is Biotin conjugated. Tested in the following application: ELISA |
|||
GP Antibody, HRP conjugated |
|||
1-CSB-PA310843LB01ZAA | Cusabio |
|
|
Description: A polyclonal antibody against GP. Recognizes GP from Zaire ebolavirus. This antibody is HRP conjugated. Tested in the following application: ELISA |
|||
GP Antibody, FITC conjugated |
|||
1-CSB-PA310843LC01ZAA | Cusabio |
|
|
Description: A polyclonal antibody against GP. Recognizes GP from Zaire ebolavirus. This antibody is FITC conjugated. Tested in the following application: ELISA |
|||
GP Antibody, Biotin conjugated |
|||
1-CSB-PA310843LD01ZAA | Cusabio |
|
|
Description: A polyclonal antibody against GP. Recognizes GP from Zaire ebolavirus. This antibody is Biotin conjugated. Tested in the following application: ELISA |
|||
GP Antibody, HRP conjugated |
|||
1-CSB-PA314099LB01ZAT | Cusabio |
|
|
Description: A polyclonal antibody against GP. Recognizes GP from Zaire ebolavirus. This antibody is HRP conjugated. Tested in the following application: ELISA |
|||
GP Antibody, FITC conjugated |
|||
1-CSB-PA314099LC01ZAT | Cusabio |
|
|
Description: A polyclonal antibody against GP. Recognizes GP from Zaire ebolavirus. This antibody is FITC conjugated. Tested in the following application: ELISA |
|||
GP Antibody, Biotin conjugated |
|||
1-CSB-PA314099LD01ZAT | Cusabio |
|
|
Description: A polyclonal antibody against GP. Recognizes GP from Zaire ebolavirus. This antibody is Biotin conjugated. Tested in the following application: ELISA |
|||
Recombinant Ebola GP (Zaire) |
|||
DAGA-3111 | Creative Diagnostics | 100ug | 1294.8 EUR |
anti- GP repeat antibody |
|||
FNab03570 | FN Test | 100µg | 702 EUR |
Description: Antibody raised against GP repeat |
|||
Mouse GP ELISA Kit |
|||
EMG0349 | Abclonal | 96Tests | 625.2 EUR |
Human GP ELISA Kit |
|||
EHG0349 | Abclonal | 96Tests | 625.2 EUR |
Rat GP ELISA Kit |
|||
ERG0349 | Abclonal | 96Tests | 625.2 EUR |
Rabbit GP ELISA Kit |
|||
ERTG0349 | Abclonal | 96Tests | 625.2 EUR |
Porcine GP ELISA Kit |
|||
EPG0349 | Abclonal | 96Tests | 625.2 EUR |
Goat GP ELISA Kit |
|||
EGTG0349 | Abclonal | 96Tests | 625.2 EUR |
Bovine GP ELISA Kit |
|||
EBG0349 | Abclonal | 96Tests | 625.2 EUR |
Canine GP ELISA Kit |
|||
ECG0349 | Abclonal | 96Tests | 625.2 EUR |
Anserini GP ELISA Kit |
|||
EAG0349 | Abclonal | 96Tests | 625.2 EUR |
Anti-GP repeat antibody |
|||
PAab03570 | Lifescience Market | 100 ug | 494.4 EUR |
Recombinant MARV GP Protein |
|||
VAng-Wyb3477-50gEcoli | Creative Biolabs | 50 µg (E. coli) | 3921.6 EUR |
Description: Lake Victoria marburg virus (strain Angola/2005) envelope glycoprotein, recombinant protein. |
|||
Inactivated VZV gp Antigen |
|||
VAng-Lsx0551-inquire | Creative Biolabs | inquire | Ask for price |
Description: VZV Glycoprotein, natural protein. |
|||
Hanna GP Penetration Probe |
|||
THE0802 | Scientific Laboratory Supplies | EACH | 68.4 EUR |
Hanna GP Liquid Probe |
|||
THE4525 | Scientific Laboratory Supplies | EACH | 87.78 EUR |
Spike (B.1.429 Variant) Pseudotyped Lentivirus (Luc Reporter) |
|||
78172-1 | BPS Bioscience | 100 µl | 835 EUR |
Description: The Spike (B.1.429 Variant) (SARS-CoV-2) Pseudotyped Lentiviruses were produced with SARS-CoV-2 B.1.429 Variant Spike (Genbank Accession #QHD43416.1 with B.1.429 variant mutations; see below for details) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (B.1.429 Variant) (SARS-CoV-2) pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 B.1.429 variant in a Biosafety Level 2 facility.Spike Mutations in B.1.429 Variant: S13I W152C L452R D614G |
|||
Spike (B.1.429 Variant) Pseudotyped Lentivirus (Luc Reporter) |
|||
78172-2 | BPS Bioscience | 500 µl x 2 | 4195 EUR |
Description: The Spike (B.1.429 Variant) (SARS-CoV-2) Pseudotyped Lentiviruses were produced with SARS-CoV-2 B.1.429 Variant Spike (Genbank Accession #QHD43416.1 with B.1.429 variant mutations; see below for details) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (B.1.429 Variant) (SARS-CoV-2) pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 B.1.429 variant in a Biosafety Level 2 facility.Spike Mutations in B.1.429 Variant: S13I W152C L452R D614G |
|||
Spike (B.1.617 Variant) Pseudotyped Lentivirus (Luc Reporter) |
|||
78204-1 | BPS Bioscience | 100 µl | 835 EUR |
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and ACE2 may offer protection against the viral infection. A variant called B.1.617 (Kappa, Delta lineage) was identified in India in the spring of 2021. This variant has a number of mutations that allow the virus to spread more easily and quickly than other variants. The Spike (B.1.617 Variant) (SARS-CoV-2) Pseudotyped Lentivirus were produced with SARS-CoV-2 B.1.617 Variant Spike (Genbank Accession #QHD43416.1 with B.1.617 mutations; see below for details) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (B.1.617 Variant) (SARS-CoV-2) pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 B.1.617 variant in a Biosafety Level 2 facility. |
|||
Spike (B.1.617 Variant) Pseudotyped Lentivirus (Luc Reporter) |
|||
78204-2 | BPS Bioscience | 500 µl x 2 | 4195 EUR |
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and ACE2 may offer protection against the viral infection. A variant called B.1.617 (Kappa, Delta lineage) was identified in India in the spring of 2021. This variant has a number of mutations that allow the virus to spread more easily and quickly than other variants. The Spike (B.1.617 Variant) (SARS-CoV-2) Pseudotyped Lentivirus were produced with SARS-CoV-2 B.1.617 Variant Spike (Genbank Accession #QHD43416.1 with B.1.617 mutations; see below for details) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (B.1.617 Variant) (SARS-CoV-2) pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 B.1.617 variant in a Biosafety Level 2 facility. |
|||
Spike (B.1.617.1 Variant) Pseudotyped Lentivirus (Luc Reporter) |
|||
78205-1 | BPS Bioscience | 100 µl | 835 EUR |
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and ACE2 may offer protection against the viral infection. A variant called B.1.617.1 (also known as the Kappa Variant) was identified in India in the spring of 2021. This variant has a number of mutations that allow the virus to spread more easily and quickly than other variants. The Spike (B.1.617.1 Variant) (SARS-CoV-2) Pseudotyped Lentivirus were produced with SARS-CoV-2 B.1.617.1 Variant Spike (Genbank Accession #QHD43416.1 with B.1.617.1 mutations; see below for details) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (B.1.617.1 Variant) (SARS-CoV-2) pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 B.1.617.1 variant in a Biosafety Level 2 facility. Spike Mutations in B.1.617.1 Variant:G142DE154KL452RE484QD614GP681RQ1071H |
|||
Spike (B.1.617.1 Variant) Pseudotyped Lentivirus (Luc Reporter) |
|||
78205-2 | BPS Bioscience | 500 µl x 2 | 4195 EUR |
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and ACE2 may offer protection against the viral infection. A variant called B.1.617.1 (also known as the Kappa Variant) was identified in India in the spring of 2021. This variant has a number of mutations that allow the virus to spread more easily and quickly than other variants. The Spike (B.1.617.1 Variant) (SARS-CoV-2) Pseudotyped Lentivirus were produced with SARS-CoV-2 B.1.617.1 Variant Spike (Genbank Accession #QHD43416.1 with B.1.617.1 mutations; see below for details) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (B.1.617.1 Variant) (SARS-CoV-2) pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 B.1.617.1 variant in a Biosafety Level 2 facility. Spike Mutations in B.1.617.1 Variant:G142DE154KL452RE484QD614GP681RQ1071H |
|||
Spike (B.1.618 Variant) Pseudotyped Lentivirus (Luc Reporter) |
|||
78206-1 | BPS Bioscience | 100 µl | 835 EUR |
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and ACE2 may offer protection against the viral infection. A variant called B.1.618 was identified in India in the spring of 2021. This variant has a number of mutations that allow the virus to spread more easily and quickly than other variants. The Spike (B.1.618 Variant) (SARS-CoV-2) Pseudotyped Lentivirus were produced with SARS-CoV-2 B.1.618 Variant Spike (Genbank Accession #QHD43416.1 with B.1.618 mutations; see below for details) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (B.1.618 Variant) (SARS-CoV-2) pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 B.1.618 variant in a Biosafety Level 2 facility. Spike Mutations in B.1.618 Variant:Y145delH146delE484KD614G |
|||
Spike (B.1.618 Variant) Pseudotyped Lentivirus (Luc Reporter) |
|||
78206-2 | BPS Bioscience | 500 µl x 2 | 4195 EUR |
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and ACE2 may offer protection against the viral infection. A variant called B.1.618 was identified in India in the spring of 2021. This variant has a number of mutations that allow the virus to spread more easily and quickly than other variants. The Spike (B.1.618 Variant) (SARS-CoV-2) Pseudotyped Lentivirus were produced with SARS-CoV-2 B.1.618 Variant Spike (Genbank Accession #QHD43416.1 with B.1.618 mutations; see below for details) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (B.1.618 Variant) (SARS-CoV-2) pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 B.1.618 variant in a Biosafety Level 2 facility. Spike Mutations in B.1.618 Variant:Y145delH146delE484KD614G |
|||
Spike (B.1.617.2 Variant) Pseudotyped Lentivirus (Luc Reporter) |
|||
78215-1 | BPS Bioscience | 100 µl | 900 EUR |
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and ACE2 may offer protection against the viral infection. A variant called B.1.617.2 (also known as the Delta Variant) was identified in India in the spring of 2021. This variant has a number of mutations that increase morbidity and mortality and allow the virus to spread more easily and quickly than other variants.The Spike (B.1.617.2 Variant) (SARS-CoV-2) Pseudotyped Lentiviruses were produced with SARS-CoV-2 B.1.617.2 Variant Spike (Genbank Accession #QHD43416.1 with B.1.617.2 mutations; see below for details) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (B.1.617.2 Variant) (SARS-CoV-2) pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 B.1.617.2 variant in a Biosafety Level 2 facility. |
|||
Spike (B.1.617.2 Variant) Pseudotyped Lentivirus (Luc Reporter) |
|||
78215-2 | BPS Bioscience | 500 µl x 2 | 4510 EUR |
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and ACE2 may offer protection against the viral infection. A variant called B.1.617.2 (also known as the Delta Variant) was identified in India in the spring of 2021. This variant has a number of mutations that increase morbidity and mortality and allow the virus to spread more easily and quickly than other variants.The Spike (B.1.617.2 Variant) (SARS-CoV-2) Pseudotyped Lentiviruses were produced with SARS-CoV-2 B.1.617.2 Variant Spike (Genbank Accession #QHD43416.1 with B.1.617.2 mutations; see below for details) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (B.1.617.2 Variant) (SARS-CoV-2) pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 B.1.617.2 variant in a Biosafety Level 2 facility. |
|||
Spike (SARS-CoV-1) Pseudotyped Lentivirus (Luc Reporter) |
|||
78614-1 | BPS Bioscience | 100 µl | 860 EUR |
Description: Severe acute respiratory syndrome (SARS) was the first new infectious disease identified in the twenty-first century. It is a viral respiratory disease caused by severe acute respiratory syndrome coronavirus (SARS-CoV-1). The first known cases occurred in November 2002, and the syndrome caused the 2002-2004 SARS outbreak. Since 2004, no cases of SARS-CoV-1 have been reported worldwide. A virus very similar to SARS-CoV-1 was discovered in late 2019. This virus, named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is the causative pathogen of COVID-19, the spread of which started the COVID-19 pandemic.SARS-CoV-1 attaches to the host cell surface before entering the cell. The Spike protein on the virus recognizes and binds to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of human airway epithelia as well as lung parenchyma. Drugs targeting the interaction between the Spike protein of SARS-CoV-1 and ACE2 may offer protection against the viral infection.The Spike (SARS-CoV-1) Pseudotyped Lentiviruses were produced with SARS-CoV-1 Spike (Genbank Accession #YP_009825051.1) as the envelope glycoprotein instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (SARS-CoV-1) pseudovirus can be used to measure the activity of a neutralizing antibody against SARS-CoV-1 in a cellular context, using a Biosafety Level 2 facility.The Spike (SARS-CoV-1) Pseudotyped Lentiviruses has been validated for use with target cells ACE2-HEK293 (which overexpress ACE2; BPS Bioscience #79951). |
|||
Spike (SARS-CoV-1) Pseudotyped Lentivirus (Luc Reporter) |
|||
78614-2 | BPS Bioscience | 500 µl x 2 | 4320 EUR |
Description: Severe acute respiratory syndrome (SARS) was the first new infectious disease identified in the twenty-first century. It is a viral respiratory disease caused by severe acute respiratory syndrome coronavirus (SARS-CoV-1). The first known cases occurred in November 2002, and the syndrome caused the 2002-2004 SARS outbreak. Since 2004, no cases of SARS-CoV-1 have been reported worldwide. A virus very similar to SARS-CoV-1 was discovered in late 2019. This virus, named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is the causative pathogen of COVID-19, the spread of which started the COVID-19 pandemic.SARS-CoV-1 attaches to the host cell surface before entering the cell. The Spike protein on the virus recognizes and binds to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of human airway epithelia as well as lung parenchyma. Drugs targeting the interaction between the Spike protein of SARS-CoV-1 and ACE2 may offer protection against the viral infection.The Spike (SARS-CoV-1) Pseudotyped Lentiviruses were produced with SARS-CoV-1 Spike (Genbank Accession #YP_009825051.1) as the envelope glycoprotein instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (SARS-CoV-1) pseudovirus can be used to measure the activity of a neutralizing antibody against SARS-CoV-1 in a cellular context, using a Biosafety Level 2 facility.The Spike (SARS-CoV-1) Pseudotyped Lentiviruses has been validated for use with target cells ACE2-HEK293 (which overexpress ACE2; BPS Bioscience #79951). |
|||
VSV-G Pseudotyped VSV Delta G (Luciferase Reporter) |
|||
78634-1 | BPS Bioscience | 100 µl | 795 EUR |
Description: The VSV-G Pseudotyped VSV Delta G (Luciferase Reporter) was produced by re-expression of VSV-G as the envelope glycoprotein using the VSV Delta G system in which VSV-G is deleted. The pseudovirions contain the firefly luciferase gene; therefore, the VSV-G mediated cell entry can be measured via luciferase activity. The VSV-G Pseudotyped VSV Delta G (Luciferase Reporter) can be used as a positive control of transduction for other VSV pseudotypes containing the envelope glycoproteins of heterologous viruses in a Biosafety Level 2 facility. |
|||
VSV-G Pseudotyped VSV Delta G (Luciferase Reporter) |
|||
78634-2 | BPS Bioscience | 500 µl x 2 | 3995 EUR |
Description: The VSV-G Pseudotyped VSV Delta G (Luciferase Reporter) was produced by re-expression of VSV-G as the envelope glycoprotein using the VSV Delta G system in which VSV-G is deleted. The pseudovirions contain the firefly luciferase gene; therefore, the VSV-G mediated cell entry can be measured via luciferase activity. The VSV-G Pseudotyped VSV Delta G (Luciferase Reporter) can be used as a positive control of transduction for other VSV pseudotypes containing the envelope glycoproteins of heterologous viruses in a Biosafety Level 2 facility. |
|||
Spike (SARS-CoV-2) Pseudotyped Lentivirus (Luciferase Reporter) |
|||
79942-1 | BPS Bioscience | 100 µl | 875 EUR |
Description: The SARS-CoV-2 Spike Pseudotyped Lentivirus were produced with SARS-CoV-2 Spike (Genbank Accession #QHD43416.1) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions also contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be conveniently measured via luciferase reporter activity. The SARS-CoV-2 Spike pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 in a Biosafety Level 2 facility._x000D_ _x000D_ |
|||
Spike (SARS-CoV-2) Pseudotyped Lentivirus (Luciferase Reporter) |
|||
79942-2 | BPS Bioscience | 500 µl x 2 | 4405 EUR |
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and ACE2 may offer protection against the viral infection._x000D_The SARS-CoV-2 Spike Pseudotyped Lentivirus were produced with SARS-CoV-2 Spike (Genbank Accession #QHD43416.1) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions also contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be conveniently measured via luciferase reporter activity. The SARS-CoV-2 Spike pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 in a Biosafety Level 2 facility._x000D_ _x000D_ |
|||
Spike (SARS-CoV-2) Pseudotyped Lentivirus (eGFP Reporter) |
|||
79981-1 | BPS Bioscience | 100 µl | 875 EUR |
Description: The SARS-CoV-2 Spike Pseudotyped Lentivirus were produced with SARS-CoV-2 Spike (Genbank Accession #QHD43416.1) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions also contain the enhanced GFP gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be conveniently determined via eGFP activity. The SARS-CoV-2 Spike pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 in a Biosafety Level 2 facility._x000D_ |
|||
Spike (SARS-CoV-2) Pseudotyped Lentivirus (eGFP Reporter) |
|||
79981-2 | BPS Bioscience | 500 µl x 2 | 5245 EUR |
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and ACE2 may offer protection against the viral infection._x000D_The SARS-CoV-2 Spike Pseudotyped Lentivirus were produced with SARS-CoV-2 Spike (Genbank Accession #QHD43416.1) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions also contain the enhanced GFP gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be conveniently determined via eGFP activity. The SARS-CoV-2 Spike pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 in a Biosafety Level 2 facility._x000D_ |
|||
Recombinant EBOV sGP Protein (aa 33-324) |
|||
VAng-0668Lsx-1mg | Creative Biolabs | 1 mg | 7318.8 EUR |
Description: Ebola virus BDBV (subtype Bundibugyo strain Uganda 2007) Small/secreted Glycoprotein (sGP), recombinant protein from HEK 293 cells with a polyhistidine tag at the C-terminus. |
|||
Recombinant EBOV sGP Protein (aa 33-324) |
|||
VAng-0668Lsx-50g | Creative Biolabs | 50 µg | 1017.6 EUR |
Description: Ebola virus BDBV (subtype Bundibugyo strain Uganda 2007) Small/secreted Glycoprotein (sGP), recombinant protein from HEK 293 cells with a polyhistidine tag at the C-terminus. |
|||
Recombinant EBOV Envelope Glycoprotein (aa 33-637) |
|||
VAng-0669Lsx-100g | Creative Biolabs | 100 µg | 1017.6 EUR |
Description: Ebola virus BDBV (subtype Zaire strain Kikwit-95) Envelope Glycoprotein (GP) containing GP1 and GP2, recombinant protein from HEK 293 cells with a polyhistidine tag at the C-terminus. |
|||
Recombinant EBOV Envelope Glycoprotein (aa 33-637) |
|||
VAng-0669Lsx-1mg | Creative Biolabs | 1 mg | 5998.8 EUR |
Description: Ebola virus BDBV (subtype Zaire strain Kikwit-95) Envelope Glycoprotein (GP) containing GP1 and GP2, recombinant protein from HEK 293 cells with a polyhistidine tag at the C-terminus. |
|||
Human CellExp? Recombinant EBOV Envelope Glycoprotein 1 |
|||
P1060-10 | Biovision | each | 170.4 EUR |
Human CellExp? Recombinant EBOV Envelope Glycoprotein 1 |
|||
P1060-50 | Biovision | each | 483.6 EUR |
Recombinant HIV gp 120 and gp 41 (aa 485-631) Protein |
|||
VAng-0525Lsx-inquire | Creative Biolabs | inquire | Ask for price |
Description: HIV Chimeric Recombinant gp120 and gp41 (a.a. 485-631), recombinant protein from E. coli. MW 43 kDa, 2.70 mg/mL. |
|||
Western blot Kit for G. pig Primary Antibodies, Chemilum. Substrate |
|||
80206-Gp | Alpha Diagnostics | 1 kit | 781.2 EUR |
SV40 large T-antigen (GFP-Puro), CMV lentiviral particles |
|||
LVP016-GP | GenTarget | 1x107 IFU/ml x 200ul | 418.8 EUR |
Description: Pre-made lentiviral particles expressing SV40 large T-antigen under suCMV promoter, containing GFP-puromycin fusion dual marker. |
|||
h PBK inducible lentiviral particles |
|||
LVP095-GP | GenTarget | 1x107 IFU/ml x 200ul | 541.2 EUR |
Description: Pre-made tet-inducible lentiviral particles expressing a human gene with a Blasticidin-RFP fusion marker (Dual selection). The expressed human gene, PBK, is fully sequence verified and matched to NCBI accession ID: NM_018492.2 |
|||
h TERT inducible lentiviral particles |
|||
LVP105-GP | GenTarget | 1x107 IFU/ml x 200ul | 541.2 EUR |
Description: Pre-made tet-inducible lentiviral particles expressing a human gene with a GFP-Puromycin fusion marker (Dual selection). The expressed human gene, TERT, is fully sequence verified and matched to NCBI accession ID: NM_198253.2 |
|||
m VSIR inducible lentiviral particles |
|||
LVP1070-GP | GenTarget | 1x107 IFU/ml x 200ul | 541.2 EUR |
Description: Pre-made over-expression lentivirus for expressing mouse target: VSIR V-set immunoregulatory receptor), [alternative names: Dies1; PD-1H; VISTA]. The sub-cloned codon sequence is identical (100% match) to CDS region in NCBI ID: NM_028732.4. It contains a GFP-Puromycin dual selection marker. |
|||
h CD274 (PDL1) (6His, GFP-Puro) inducible lentiviral particles |
|||
LVP1077-GP | GenTarget | 1x107 IFU/ml x 200ul | 541.2 EUR |
Description: Pre-made over-expression lentivirus for expressing C-terminal His-Taggedhuman target: CD274 (6His) (human CD274 molecule), [alternative names: B7-H; B7H1; PD-L1; PDCD1L1; PDCD1LG1; PDL1]. The sub-cloned codon sequence is identical (100% match) to CDS region in NCBI ID: NM_014143.3. It contains a GFP-Puromycin dual selection marker. |
|||
h CD19 (GFP-Pueo) Lentivirus |
|||
LVP1084-GP | GenTarget | 1x107 IFU/ml x 200ul | 541.2 EUR |
Description: Pre-made over-expression lentivirus for expressing human target: CD19 (human CD19 molecule), [alternative names: B4; CVID3]. The sub-cloned codon sequence is identical (100% match) to CDS region in NCBI ID: NM_001178098.1. It contains a GFP-Puromycin dual selection marker. |
|||
h SF3B1 (GFP-Puro) |
|||
LVP1111-GP | GenTarget | 1x107 IFU/ml x 200ul | 541.2 EUR |
Description: Pre-made over-expression lentivirus for expressing human target: SF3B1 (splicing factor 3b subunit 1), [alternative names: Hsh155; MDS; PRP10; PRPF10; SAP155; SF3b155]. The sub-cloned codon sequence is identical (100% match) to CDS region in NCBI ID: NM_012433. It also contains a GFP-Puromycin dual selection marker. |
|||
h SRSF2 (GFP-Puro) |
|||
LVP1112-GP | GenTarget | 1x107 IFU/ml x 200ul | 541.2 EUR |
Description: Pre-made over-expression lentivirus for expressing human target: SRSF2 (serine and arginine rich splicing factor 2), [alternative names: PR264; SC-35; SC35; SFRS2; SFRS2A; SRp30b]. The sub-cloned codon sequence is identical (100% match) to CDS region in NCBI ID: NM_003016. It also contains a GFP-Puromycin dual selection marker. |
|||
h U2AF1 (GFP-Puro) |
|||
LVP1113-GP | GenTarget | 1x107 IFU/ml x 200ul | 541.2 EUR |
Description: Pre-made over-expression lentivirus for expressing human target: U2AF1 (U2 small nuclear RNA auxiliary factor 1), [alternative names: FP793; RN; RNU2AF1; U2AF35; U2AFBP]. The sub-cloned codon sequence is identical (100% match) to CDS region in NCBI ID: NM_001025203. It also contains a GFP-Puromycin dual selection marker. |
|||
h ZRSR2 (GFP-Puro) |
|||
LVP1118-GP | GenTarget | 1x107 IFU/ml x 200ul | 541.2 EUR |
Description: Pre-made over-expression lentivirus for expressing human target: ZRSR2 (zinc finger CCCH-type, RNA binding motif and serine/arginine rich 2), [alternative names: U2AF1-RS2; U2AF1L2; U2AF1RS2; URP; ZC3H22]. The sub-cloned codon sequence is identical (100% match) to CDS region in NCBI ID: NM_005089. It also contains a GFP-Puromycin dual selection marker. |
|||
h RBM10 (GFP-Puro) Lentivirus |
|||
LVP1124-GP | GenTarget | 1x107 IFU/ml x 200ul | 541.2 EUR |
Description: Pre-made over-expression lentivirus for expressing human target: RBM10 (RNA binding motif protein 10), [alternative names: DXS8237E; GPATC9; GPATCH9; S1-1; TARPS; ZRANB5]. The sub-cloned codon sequence is identical (100% match) to CDS region in NCBI ID: NM_005676.4 . It also contains a GFP-Puromycin dual selection marker. |
|||
h AKR1C3 (GFP-Puro) inducible lentiviral particles |
|||
LVP1129-GP | GenTarget | 1x107 IFU/ml x 200ul | 541.2 EUR |
Description: Premade lentivirus natively over-express human AKR1C3 gene. It contains a GFP_Puromycin fusion dual marker. |
|||
hTERT (CMV, GFP-Puro) lentivirus |
|||
LVP1130-GP | GenTarget | 1x107 IFU/ml x 200ul | 418.8 EUR |
Description: Premade lentivirus expressing human TERT gene under suCMV promoter, containing GFP-Puromycin fusion dual marker. |
|||
hTERT (EF1a, GFP-Puro) lentivirus |
|||
LVP1131-GP | GenTarget | 1x107 IFU/ml x 200ul | 418.8 EUR |
Description: Premade lentivirus expressing human TERT gene under EF1a promoter, containing GFP-Puromycin fusion dual marker. |
|||
EBNA1 (GFP-Puro) Lentivirus |
|||
LVP1134-GP | GenTarget | 1x107 IFU/ml x 200ul | 418.8 EUR |
Description: Premade lentivirus expressing Epstein Barr Virus' EBNA1 gene under EF1a promoter, containing GFP-Puromycin dual marker. |
|||
EBNA2 (GFP-Puro) Lentivirus |
|||
LVP1135-GP | GenTarget | 1x107 IFU/ml x 200ul | 418.8 EUR |
Description: Premade lentivirus expressing Epstein Barr Virus' EBNA2 gene under EF1a promoter, containing GFP-Puromycin dual marker. |
|||
HpV16-E6 (GFP-Puro) Lentivirus |
|||
LVP1136-GP | GenTarget | 1x107 IFU/ml x 200ul | 418.8 EUR |
Description: Premade lentivirus expressing HpV16 virus' E6 gene under EF1a promoter, containing GFP-Puromycin dual marker. |
|||
E1A (GFP-Puro) Lentivirus |
|||
LVP1137-GP | GenTarget | 1x107 IFU/ml x 200ul | 418.8 EUR |
Description: Premade lentivirus expressing Adenovirus type 5's E1A gene under EF1a promoter, containing GFP-Puromycin dual marker. |
|||
HOXA9 (GFP-Puro) Lentivirus |
|||
LVP1138-GP | GenTarget | 1x107 IFU/ml x 200ul | 418.8 EUR |
Description: Premade lentivirus expressing human HOXA9 gene under EF1a promoter, containing GFP-Puromycin dual marker. |
|||
KRas_G12V (GFP-Puro) Lentivirus |
|||
LVP1139-GP | GenTarget | 1x107 IFU/ml x 200ul | 418.8 EUR |
Description: Premade lentivirus expressing human Kras V12G mutant under EF1a promoter, containing GFP-Puromycin dual marker. |
|||
CDK4 (GFP-Puro) Lentivirus |
|||
LVP1140-GP | GenTarget | 1x107 IFU/ml x 200ul | 418.8 EUR |
Description: Premade lentivirus expressing human CDK4 gene under EF1a promoter, containing GFP-Puromycin dual marker. |
|||
cMyc (GFP-Puro) Lentivirus |
|||
LVP1141-GP | GenTarget | 1x107 IFU/ml x 200ul | 418.8 EUR |
Description: Premade lentivirus expressing human cMyc gene under EF1a promoter, containing GFP-Puromycin dual marker. |
|||
NATtrol Norovirus Group I (Recombinant) (Stool Matrix) (0.5 mL) |
|||
NATNOVI-GP | Zeptometrix | 0.5 mL | 112.42 EUR |
Description: Please contact Gentaur in order to receive the datasheet of the product. |
|||
NATtrol Norovirus Group II (Recombinant) (Stool Matrix) (0.5 mL) |
|||
NATNOVII-GP | Zeptometrix | 0.5 mL | 112.42 EUR |
Description: Please contact Gentaur in order to receive the datasheet of the product. |
|||
NATtrol Rotavirus (Stool Matrix) (0.5 mL) |
|||
NATROTA-GP | Zeptometrix | 0.5 mL | 112.42 EUR |
Description: Please contact Gentaur in order to receive the datasheet of the product. |
|||
NATtrol Shigella sonnei (Stool Matrix) (0.5 mL) |
|||
NATSSO-GP | Zeptometrix | 0.5 mL | 112.42 EUR |
Description: Please contact Gentaur in order to receive the datasheet of the product. |
|||
NATtrol Salmonella typhimurium (Stool Matrix) (0.5 mL) |
|||
NATSTY-GP | Zeptometrix | 0.5 mL | 112.42 EUR |
Description: Please contact Gentaur in order to receive the datasheet of the product. |
|||
NATtrol Adenovirus Type 40 (Stool Matrix) (0.5 mL) |
|||
NATADV40-GP | Zeptometrix | 0.5 mL | 112.42 EUR |
Description: Please contact Gentaur in order to receive the datasheet of the product. |
|||
NATtrol Adenovirus Type 41 (Stool Matrix) (0.5 mL) |
|||
NATADV41-GP | Zeptometrix | 0.5 mL | 112.42 EUR |
Description: Please contact Gentaur in order to receive the datasheet of the product. |